The following information is presented for educational purposes only. Medical Marijuana Inc. provides this information to provide an understanding of the potential applications of cannabidiol. Links to third party websites do not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred.
Crohn’s disease is a type of inflammatory bowel disease that is prevalent among adolescents and young adults. Studies have shown marijuana to be effective at decreasing digestive tract inflammation, and in some cases, helping patients achieve long-term remission.
Overview of Crohn’s Disease
Crohn’s disease is an inflammatory bowel disease (IBD) that causes the lining of the digestive tract to become inflamed. The disease may affect as many as 700,000 Americans, according to the Crohn’s & Colitis Foundation of America, causing abdominal pain, rectal bleeding, severe diarrhea, fever, weight loss, fatigue and malnutrition. The pain can be so intense that it becomes debilitating. In some cases, the disease can prove to be life-threatening.
According to Mayo Clinic, the most common area of the digestive tract affected by Crohn’s disease is at the end of the small bowel (the ileum) and the beginning of the colon. The disease can affect any part of the digestive tract, however, and will often spread deep into the layers of bowel tissue.
Heredity and abnormal immune system behavior are likely what cause Crohn’s disease to develop. Those who have family members with the disease are more common to acquire it themselves. When the immune system responds to fight off a virus, bacteria, fungi and other microorganisms, at times it can respond abnormally and also attack the harmless cells in the digestive tract, which in turn leads to inflammation.
There is no confirmed cure for Crohn’s disease, but certain treatment methods can significantly reduce symptoms and in some cases, even bring about remission. Treatment efforts primarily include antibiotics, and anti-inflammatory, anti-diarrhea and pain relief medications to manage the symptoms associated with the disease. In some cases, the use of a feeding tube to allow the digestive tract to rest and decrease inflammation, or surgery to remove the damaged portion of the digestive tract, may be required.
Findings: Effects of Cannabis on Crohn’s Disease
Studies have found cannabis to effectively combat the symptoms associated with Crohn’s disease. Cannabinoids provide anti-inflammatory effects, subsequently reducing pain, offering nausea relief, and reducing the feelings of unpleasantness4,11. One study, in which inflammatory bowel disease patients were treated with cannabis for three months, improvements in the patients’ general health perception, social functioning, ability to work, physical pain and depression were found. Participants also saw increases in body weight and BMI6. In another study, patients suffering from inflammatory bowel disease reported that marijuana was “very helpful” in relieving their abdominal pain, nausea and diarrhea10. Cannabis has also been found to reduce depression, gut pain, and fatigue, and improve appetite, activity and sleep in Crohn’s disease patients2,5. In what is likely due to cannabis’ ability to improve symptoms associated with Crohn’s disease, medical cannabis has also been associated with a reduced need of other medications in patients with Crohn’s disease8.
Research also suggests that cannabis may be effective at helping Crohn’s disease reach long-term remission. Medical cannabis use has been determined to be associated with an improvement in disease activity9. In one study, cannabis rich in tetrahydrocannabinol (THC) produced significant benefits to 10 or 11 patients with active Crohn’s disease, without side effects, and 5 of those 11 subjects achieved complete remission8. In another, 21 or 30 patients with Crohn’s disease significantly improved after treatment with cannabis. Cannabis was shown to have a positive effect on disease activity and reduced the need for other drugs and surgery7.
States That Have Approved Medical Marijuana for Crohn’s Disease
Currently, 22 states have approved medical marijuana to be used to treat Crohn’s disease. These states include: Arizona, Arkansas, Connecticut, Florida, Georgia, Hawaii, Illinois, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Montana, New Hampshire, New Jersey, New Mexico, New York (inflammatory bowel disease), North Dakota, Ohio, Pennsylvania, Rhode Island, Washington, and West Virginia.
A number of other states will allow medical marijuana to be used for the treatment of Crohn’s Disease, but require an approval or a recommendation by a physician. These states include: California (any debilitating illness where the medical use of marijuana has been recommended by a physician), Nevada (other conditions subject to approval), and Oregon (other conditions subject to approval).
In Washington D.C., any condition can be approved for medical marijuana as long as a DC-licensed physician recommends the treatment.
Studies on Cannabis’ Effect on Crohn’s Disease
- Crohn’s disease. (2014, August 13). Mayo Clinic. Retrieved from http://www.mayoclinic.org/diseases-conditions/crohns-disease/basics/definition/con-20032061.
- Fouad, A.A., and Jresat, I. (2011, November 16). Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats. European Journal of Pharmacology, 670(1), 216-23. Retrieved from http://www.sciencedirect.com/science/article/pii/S0014299911009599.
- Fouad, A.A., Al-Mulhim, A.S., and Gomaa, W. (2013, October). Protective effect of cannabidiol against cadmium hepatoxicity in rats. Journal of Trace Elements in Medicine and Biology, 27(4), 355-363. Retrieved from http://www.sciencedirect.com/science/article/pii/S0946672X13000953.
- Hergenrather, J. (2005, Autumn). Cannabis alleviates symptoms of Crohn’s disease. O’Shaughnessy’s. Retrieved from http://cannabisclinicians.org/wp-content/uploads/2012/02/Cannabis-for-Crohns-Disease.pdf.
- Jamontt, J., Molleman, A., Pertwee, R., and Parsons, M. (2010). The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. British Journal of Pharmacology, 160(3), 712–723. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931570/.
- Lahat, A., Lang, A., and Ben-Horin, S. (2012). Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion, 85(1), 1-8. Retrieved from https://www.karger.com/Article/Purchase/332079.
- Naftali, T., Lev, L.B., Yablecovitch, D., Half, E., and Konikoff, F.M. (2011, August). Treatment of Crohn’s disease with cannabis: An observational study. The Israel Medical Association Journal, 13(8), 455-8. Retrieved from https://www.ima.org.il/FilesUpload/IMAJ/0/39/19985.pdf.
- Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P. Sklerovsky Benjaminov, F. and Konikoff, FM. (2013, October). Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology, 11(10), 1276-1280. Retrieved from http://www.cghjournal.org/article/S1542-3565(13)00604-6/fulltext.
- Naftali, T., Mechulam, R., Lev, L.B., and Konikoff, FM. (2014). Cannabis for inflammatory bowel disease. Digestive Diseases, 32(4), 468-74. Retrieved from https://www.karger.com/Article/Purchase/358155.
- Ravikoff Allegretti, J., Courtwright, A., Lucci, M., Korzenik, J.R., and Levine, J. (2013, December). Marijuana use patterns among patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 19(13), 2809-14. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126607/.
- Schicho, R., and Storr, M. (2014). Cannabis finds its way into treatment of Crohn’s disease. Pharmacology, 93(1-2), 1-3. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076530/.
- What Are Crohn’s & Colitis? (n.d.). Crohn’s & Colitis. Retrieved from http://www.ccfa.org/what-are-crohns-and-colitis/what-is-crohns-disease/.
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.